JAKARTA – PT Indofarma (Persero) Tbk (INAF) obtains a loan worth IDR 199.86 billion from PT Bio Farma (Persero) to develop medical equipment and herbal medicines. Corporate Secretary of Indofarma, Warjoko Sumedi, announces and confirms the news.
It is further mentioned that the said facility does not come with an interest rate for the first nine years. In the tenth year, an 7.99% annual interest rate would be applied and paid every three months should its cash flow improve then. “The loan is equivalent to approximately 46.44% of the company’s equity reported in December 2020 of IDR 430.26 billion,” Sumedi further reveals.
According to Sumedi, the reason why the company opts for a loan from its parent company is to enhance synergy within the state-owned pharmaceutical holding. It could also provide INAF a facility with more competitive interest and period.
INAF records an authorised capital of IDR 1 trillion, while its issued and paid-up capital amounts to IDR 309.92 billion. The shares are divided among the government of 0.02%, PT Bio Farma 80.644%, PT Asabri (Persero) – National Military Pension Fund 7.342%, and the public 11.944%. (LK/ZH)